Although the oncogenic potential and resistance to RAF inhibitor of BRAF(ΔNVTAP) has been reported recently [31, 34], whether all BRAF mutants with in-frame deletions of β3-αC loop are able to function as cancer drivers and their pharmacological characteristics are not clear. Here, RAF1 is linked to cancer.